RecruitingPhase 2NCT07001150

Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Clinical Study Evaluating the Possible Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Sponsor

Tanta University

Enrollment

50 participants

Start Date

May 10, 2025

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease

Summary

Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.

Eligibility

Min Age: 45 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether silymarin — a natural extract from milk thistle — can help protect the brain and reduce symptoms in people with Parkinson's disease who are already taking standard dopamine replacement medication. **You may be eligible if...** - You are between 45 and 65 years old - You have been diagnosed with Parkinson's disease and are currently on dopamine replacement therapy - Your Parkinson's is at a mild to moderately advanced stage (Hoehn and Yahr stage 1–4) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have a known allergy to silymarin or multivitamins - You have advanced liver disease - You have severe obesity (BMI over 40) or poorly controlled diabetes - You are currently taking silymarin or have taken it in the past 2 weeks - You have another serious illness such as cancer or multi-organ failure Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGlevodopa-carbidopa

Carbidopa/levodopa is a combination of two medications: carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease. The main and most effective treatment strategy for motor symptoms in Parkinson's disease relies on replenishing dopamine levels through the use of L-dopa.

DRUGSilymarin

Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, is employed clinically for managing hepatic disorders. Its antioxidant effects are primarily attributed to its ability to scavenge free radicals.